Is in OMS201 are contained in generic, FDA-approved drugs that have been marketed in the United States. PDE10 Program – OMS824 Phosphodiesterase 10, or PDE10, is an enzyme that is expressed in areas of the brain strongly linked to diseases that affect cognition, including schizophrenia and Huntington’s disease. The company’s proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders, including schizophrenia where OMS824 may have a beneficial effect on the positive (e.g., hallucinations), negative (e.g., flat affect) and cognitive symptoms of the disease. PPARg Program – OMS405 In its peroxisome proliferator-activated receptor gamma, or PPARg, program, the company is in the process of developing proprietary compositions that include PPARg agonists for the treatment and prevention of addiction to substances of abuse, which may include opioids, nicotine and alcohol. The company’s collaborators at The New York State Psychiatric Institute are conducting two Phase 2 clinical trials for its PPARg program. These studies are evaluating a PPARg agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine. The National Institute on Drug Abuse is providing substantially all of the funding for these clinical trials. Intellectual Property As of February 15, 2013, the company owned or held worldwide exclusive licenses to a total of 41 issued or allowed patents and 51 pending patent applications in the United States and 167 issued or allowed patents and 163 pending patent applications in foreign markets directed to therapeutic compositions and methods related to its development programs. As of February 15, 2013, its patent portfolio included 17 U.S. and 67 foreign issued or allowed patents, and 8 U.S. and 19 foreign pending patent applications, directed to its PharmacoSurgery products and development programs. Research and Development The company has built a research and development organization that includes expertise in discovery research, preclinical development, product formulation, analytical and medicinal chemistry, manufacturing, clinical development and regulatory and quality assurance. Its research and development expenses were $31.9 million in 2012. Regulation In the United States, the company’s products are regulated by the FDA as drugs or biologics under the Federal Food, Drug, and Cosmetic Act and implementing regulations and, in the case of biologics, also under the Public Health Service Act. Before its products may be marketed in the United States, each must be approved by the FDA. History Omeros Corporation was founded in 1994.
omeros corp (OMER:NASDAQ GM)
201 Elliott Avenue West
Seattle, WA 98119
|No competitor information is available for OMER.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.